Back to News
Mar 19, 2026 12:01 PM

Eli Lilly Says Experimental Diabetes Drug Shows Weight Loss Of 17%

Eli Lilly and Co (NYSE:LLY) shares are down on Thursday. The company released news regarding its investigational drug, retatrutide, which has shown promising results in clinical trials.

Eli Lilly Retatrutide Shows Strong A1C Reduction And Weight Loss

Retatrutide is an investigational once-weekly triple hormone receptor agonist that activates the body’s receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.

In the latest updates, Eli Lilly announced that retatrutide significantly lowered A1C (blood sugar) levels by an average of 1.7% to 2.0% over 40 weeks in the TRANSCEND-T2D-1 trial.

Participants taking the 12 mg dose also lost an average of 36.6 lbs (16.8%), with no plateau ...